Document is current
Any future updates will be listed below
-
Authors
Galeano-Valle, F. https://orcid.org/0000-0003-1321-6866
Pérez-Rus, G.
Demelo-Rodríguez, P.
Ordieres-Ortega, L.
Ortega-Morán, L.
Muñoz-Martín, A. J.
Medina-Molina, S.
Alvarez-Sala-Walther, L. A.
del-Toro-Cervera, J.
-
Funding
Funding for this research was provided by:
Laboratorios Farmacéuticos Rovi. S.A.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid (Programa Intramural IiSGM de impulso a la I+D+i 2018)
- License Information
-
More Information
Article History
Received: 18 October 2019
Accepted: 2 December 2019
First Online: 20 December 2019
Compliance with ethical standards
:
: Gloria Pérez-Rus: Consulting or Advisory Role: Rovi, Techdow; Speakers’ Bureau: Rovi, Amgen, Boehringer. Pablo Demelo-Rodriguez: Consulting or Advisory Role: Boehringer, LEO Pharma, Ingelheim, Techdow; Speakers’ Bureau: Rovi, Sanofi and Aspen. Jorge del-Toro-cervera: Consulting or Advisory Role: Boehringer, Ingelheim, Techdow; Speakers’ Bureau: Rovi, Sanofi and Aspen. Laura Ortega Morán: Speakers’ Bureau: Sanofi, Amgen, Merck; Travel, Accommodations, Expenses: Sanofi, Roche, Leo Pharma. Andrés J. Muñoz Martín: Consulting or Advisory Role: Celgene, Sanofi, Pfizer, LEO Pharma, Daiichi Sankyo, Bayer, Halozyme; Speakers’ Bureau: Rovi; Research Funding: Sanofi, LEO Pharma; Patents, Royalties, Other Intellectual Property: Risk assessment model in venous thromboembolism in patients with cancer; Travel, Accommodations, Expenses: Celgene, Roche, Merck Serono.
: The Institutional Ethics Committee approved the study. Participants were assured confidentiality and privacy of all collected information.
: A signed informed consent was obtained from the patients before their inclusion in the study.
